vs
Side-by-side financial comparison of Agilent Technologies (A) and APTARGROUP, INC. (ATR). Click either name above to swap in a different company.
Agilent Technologies is the larger business by last-quarter revenue ($1.8B vs $962.7M, roughly 1.9× APTARGROUP, INC.). Agilent Technologies runs the higher net margin — 17.0% vs 7.7%, a 9.2% gap on every dollar of revenue. On growth, APTARGROUP, INC. posted the faster year-over-year revenue change (13.5% vs 7.0%). Agilent Technologies produced more free cash flow last quarter ($175.0M vs $96.9M). Over the past eight quarters, Agilent Technologies's revenue compounded faster (6.9% CAGR vs 2.6%).
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emissi...
AptarGroup, Inc., also known as Aptar, is a United States–based global manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.
A vs ATR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.8B | $962.7M |
| Net Profit | $305.0M | $74.3M |
| Gross Margin | 52.6% | — |
| Operating Margin | 19.6% | 11.0% |
| Net Margin | 17.0% | 7.7% |
| Revenue YoY | 7.0% | 13.5% |
| Net Profit YoY | -4.1% | -26.4% |
| EPS (diluted) | $1.07 | $1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $962.7M | ||
| Q3 25 | $1.7B | $961.1M | ||
| Q2 25 | $1.7B | $966.0M | ||
| Q1 25 | $1.7B | $887.3M | ||
| Q4 24 | $1.7B | $848.1M | ||
| Q3 24 | $1.6B | $909.3M | ||
| Q2 24 | $1.6B | $910.1M |
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $74.3M | ||
| Q3 25 | $336.0M | $127.9M | ||
| Q2 25 | $215.0M | $111.7M | ||
| Q1 25 | $318.0M | $78.8M | ||
| Q4 24 | $351.0M | $100.9M | ||
| Q3 24 | $282.0M | $100.0M | ||
| Q2 24 | $308.0M | $90.5M |
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | — | ||
| Q3 25 | 51.1% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 53.5% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 54.4% | — |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | 11.0% | ||
| Q3 25 | 20.7% | 14.2% | ||
| Q2 25 | 18.0% | 14.9% | ||
| Q1 25 | 22.4% | 12.8% | ||
| Q4 24 | 24.0% | 14.2% | ||
| Q3 24 | 21.1% | 15.2% | ||
| Q2 24 | 23.1% | 13.8% |
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | 7.7% | ||
| Q3 25 | 19.3% | 13.3% | ||
| Q2 25 | 12.9% | 11.6% | ||
| Q1 25 | 18.9% | 8.9% | ||
| Q4 24 | 20.6% | 11.9% | ||
| Q3 24 | 17.9% | 11.0% | ||
| Q2 24 | 19.6% | 9.9% |
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $1.13 | ||
| Q3 25 | $1.18 | $1.92 | ||
| Q2 25 | $0.75 | $1.67 | ||
| Q1 25 | $1.11 | $1.17 | ||
| Q4 24 | $1.23 | $1.48 | ||
| Q3 24 | $0.97 | $1.48 | ||
| Q2 24 | $1.05 | $1.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.8B | $409.5M |
| Total DebtLower is stronger | $3.0B | $1.1B |
| Stockholders' EquityBook value | $6.9B | $2.7B |
| Total Assets | $12.8B | $5.3B |
| Debt / EquityLower = less leverage | 0.44× | 0.43× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $409.5M | ||
| Q3 25 | $1.5B | $264.8M | ||
| Q2 25 | $1.5B | $169.8M | ||
| Q1 25 | $1.5B | $136.8M | ||
| Q4 24 | $1.3B | $226.2M | ||
| Q3 24 | $1.8B | $327.9M | ||
| Q2 24 | $1.7B | $223.9M |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $1.1B | ||
| Q3 25 | $3.4B | $546.0M | ||
| Q2 25 | $3.3B | $535.1M | ||
| Q1 25 | $3.3B | $561.2M | ||
| Q4 24 | $3.3B | $688.1M | ||
| Q3 24 | $2.1B | $822.7M | ||
| Q2 24 | $2.1B | $681.5M |
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $2.7B | ||
| Q3 25 | $6.4B | $2.8B | ||
| Q2 25 | $6.1B | $2.7B | ||
| Q1 25 | $6.0B | $2.5B | ||
| Q4 24 | $5.9B | $2.5B | ||
| Q3 24 | $5.9B | $2.5B | ||
| Q2 24 | $6.2B | $2.4B |
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $5.3B | ||
| Q3 25 | $12.2B | $5.1B | ||
| Q2 25 | $12.2B | $4.9B | ||
| Q1 25 | $11.9B | $4.5B | ||
| Q4 24 | $11.8B | $4.4B | ||
| Q3 24 | $11.0B | $4.6B | ||
| Q2 24 | $10.9B | $4.5B |
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | 0.43× | ||
| Q3 25 | 0.53× | 0.20× | ||
| Q2 25 | 0.55× | 0.20× | ||
| Q1 25 | 0.56× | 0.22× | ||
| Q4 24 | 0.57× | 0.28× | ||
| Q3 24 | 0.36× | 0.32× | ||
| Q2 24 | 0.34× | 0.28× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $268.0M | $183.7M |
| Free Cash FlowOCF − Capex | $175.0M | $96.9M |
| FCF MarginFCF / Revenue | 9.7% | 10.1% |
| Capex IntensityCapex / Revenue | 5.2% | 9.0% |
| Cash ConversionOCF / Net Profit | 0.88× | 2.47× |
| TTM Free Cash FlowTrailing 4 quarters | $993.0M | $299.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $183.7M | ||
| Q3 25 | $362.0M | $177.6M | ||
| Q2 25 | $221.0M | $126.0M | ||
| Q1 25 | $431.0M | $82.7M | ||
| Q4 24 | $481.0M | $178.2M | ||
| Q3 24 | $452.0M | $229.3M | ||
| Q2 24 | $333.0M | $143.6M |
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $96.9M | ||
| Q3 25 | $259.0M | $114.3M | ||
| Q2 25 | $107.0M | $62.5M | ||
| Q1 25 | $334.0M | $25.9M | ||
| Q4 24 | $388.0M | $112.2M | ||
| Q3 24 | $360.0M | $162.7M | ||
| Q2 24 | $230.0M | $75.4M |
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | 10.1% | ||
| Q3 25 | 14.9% | 11.9% | ||
| Q2 25 | 6.4% | 6.5% | ||
| Q1 25 | 19.9% | 2.9% | ||
| Q4 24 | 22.8% | 13.2% | ||
| Q3 24 | 22.8% | 17.9% | ||
| Q2 24 | 14.6% | 8.3% |
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 9.0% | ||
| Q3 25 | 5.9% | 6.6% | ||
| Q2 25 | 6.8% | 6.6% | ||
| Q1 25 | 5.8% | 6.4% | ||
| Q4 24 | 5.5% | 7.8% | ||
| Q3 24 | 5.8% | 7.3% | ||
| Q2 24 | 6.5% | 7.5% |
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | 2.47× | ||
| Q3 25 | 1.08× | 1.39× | ||
| Q2 25 | 1.03× | 1.13× | ||
| Q1 25 | 1.36× | 1.05× | ||
| Q4 24 | 1.37× | 1.77× | ||
| Q3 24 | 1.60× | 2.29× | ||
| Q2 24 | 1.08× | 1.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
